| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 6, 2018Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
06 Dec 2018 KING OF PRUSSIA, Pa. – December 6, 2018 – Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal’s Most Admired CEOs for 2018,...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Oct 22, 2018Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region
22 Oct 2018 PHILADELPHIA, Pa. – October 22, 2018 – The University City Science Center and global biotechnology leader CSL Behring, which has its operational headquarters in King of Prussia,...
-
Oct 22, 2018ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency
22 Oct 2018 LISBON, Portugal – 22 October 2018 – Global biotherapeutics leader CSL Behring today announced that it will host a panel of cross-specialty experts at its “Current and Emerging...
-
Oct 9, 2018CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
09 Oct 2018 Melbourne, 9 October, 2018 – CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts. The...
-
Sep 18, 2018Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
18 Sep 2018 KING OF PRUSSIA, Pa. – September 18, 2018 – Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and...
-
Sep 13, 2018• Hosts Patient-Focused Symposium on Alpha 1 Management • Raises Money to Support Disease Awareness
13 Sep 2018 PARIS, France – 13 September 2018 – Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 17 September, during the 28th
-
Aug 23, 2018- The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size - IDELVION is now offered in 5 convenient vial sizes to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU - New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
23 Aug 2018 KING OF PRUSSIA, Pa. – 23 August 2018 – Global biotherapeutics leader CSL Behring today announced that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein...
-
Jul 20, 2018• Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP
• CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin...